Skip to main content
. Author manuscript; available in PMC: 2024 Dec 1.
Published in final edited form as: Cancer. 2023 Aug 20;129(23):3761–3771. doi: 10.1002/cncr.34980

Table 2.3:

Symptom Prevalence for LGG Group by Treatment (Any Adjuvant vs. No Adjuvant)*

Adjuvant Treatment (n = 215) No Adjuvant Treatment (n = 103) Difference Between Groups

Symptom No. % No. % P-Value
Driving Deficit 56 30.9 38 40.0 p = 0.13

Seizure 27 14.8 12 12.6 p = 0.61

Weakness in an Arm or Leg 56 30.8 28 29.5 p = 0.82

Difficulty Getting Words Out 106 58.6 59 62.1 p = 0.57

Difficulty Remembering New Facts 122 67.4 54 56.8 p = 0.08

Headache 89 49.4 55 57.9 p = 0.18

Personality Change 68 37.4 40 42.1 p = 0.44

Visual Disturbance 67 37.0 45 47.4 p = 0.10

Decreased Sensation in Face, Arms, or Legs 130 71.8 68 71.6 p = 0.97

Trouble Thinking 111 61.3 55 57.9 p = 0.58
*

In past 7 days

Note: Sample sizes vary due to missing values.